Why Asthma Research Is Having a Moment
Asthma affects roughly 25 million people in the United States, and around 2 million of those cases are classified as severe. What makes this moment noteworthy is the pace of change. Just this year, the U.S. approved Breztri Aerosphere as the first triple-combination maintenance inhaler for patients aged 12 and older—a single device delivering three medications that previously required separate prescriptions. Around the same time, a new ultra-long-acting biologic called depemokimab entered the market, requiring only two injections per year instead of the monthly or biweekly schedule that earlier biologics demanded.
These developments do not happen in a vacuum. They are the direct result of volunteers stepping into clinical trial sites across the country—from the University of Arizona's airway research center in Tucson to the Northwestern Airways Disease Center in Chicago. Each approved therapy represents years of data collection, and the pipeline shows no sign of slowing. Industry reports indicate dozens of asthma-related studies actively recruiting participants across all 50 states, covering everything from pediatric inhaler comparisons to biologic therapies for patients who have exhausted standard options.
What this means for someone living with asthma is that the research landscape is more diverse than ever. Trials are not just for severe cases anymore. There are observational studies requiring little more than lung function tests and questionnaires, interventional studies testing new inhaler formulations, and long-term biologic trials for people whose symptoms remain uncontrolled despite using high-dose maintenance therapy.
The Real Landscape of Asthma Trials
Not all asthma clinical trials look the same, and understanding the differences can save you from signing up for something that does not match your needs or comfort level.
Interventional trials study a specific treatment—perhaps a new inhaler, a biologic injection, or an oral medication. These are what most people picture when they hear "clinical trial." Participants are typically randomized into groups, with some receiving the investigational treatment and others receiving a placebo or standard care. The Teva-sponsored FpA-AS-30094 study, for instance, is exploring whether a fixed-dose combination of fluticasone propionate and albuterol sulfate can prevent exacerbations. These trials often involve multiple clinic visits, blood draws, and daily symptom diaries.
Observational studies, by contrast, collect data without changing your treatment. Researchers might track lung function over time, study how asthma affects daily life, or analyze the relationship between environmental triggers and symptom patterns. The Mount Sinai WTC asthma study, currently recruiting in New York, falls into this category—it examines self-management strategies for World Trade Center responders with asthma without introducing a new drug.
Pediatric trials focus specifically on children and adolescents, and they come with additional safeguards. The American Lung Association's Airways Clinical Research Centers network runs several pediatric studies, including trials comparing inhaler types for teenagers. Parents often find comfort in the level of monitoring these studies provide, which can exceed what a typical pediatrician visit offers.
| Trial Type | Time Commitment | Compensation Range | Best For | Key Consideration |
|---|
| Interventional (inhaler study) | 3-12 months, 6-15 visits | Varies by site; some offer stipends for each visit | Patients with uncontrolled symptoms on current regimen | May involve placebo arm |
| Biologic trial | 12-24 months, 8-20 visits | Higher due to longer commitment | Severe asthma patients who have not responded to standard therapies | Requires regular injections or infusions |
| Observational study | 1-6 months, 2-6 visits | Typically modest; may cover travel | Anyone with diagnosed asthma, including mild cases | No treatment change involved |
| Pediatric/adolescent trial | 3-12 months, 5-12 visits | Similar to adult trials; parent/guardian involvement required | Children aged 6-17 with persistent asthma | Additional consent and safety monitoring |
| Focus group or survey | Single session, 1-3 hours | Often $100-$350 per session | Patients with varied asthma experiences | No medical benefit; purely for research input |
Finding the Right Trial Without Getting Lost
ClinicalTrials.gov remains the gold standard for searching studies. Maintained by the National Library of Medicine, it lists every registered trial with detailed eligibility criteria, locations, and contact information. The search function lets you filter by condition, location, study phase, and whether the trial is currently recruiting. Typing "asthma" and your city name into the search bar will pull up opportunities near you—and the difference between "recruiting," "active but not recruiting," and "completed" statuses matters more than you might think.
Beyond the federal database, the Asthma and Allergy Foundation of America (AAFA) and the American Lung Association both maintain curated lists of asthma studies. The American Lung Association's Airways Clinical Research Centers, located in cities including Tucson, Chicago, New York, Durham, and Burlington, run trials that are federally funded rather than industry-sponsored—a distinction that matters to some participants.
Major academic medical centers also operate their own trial finders. Weill Cornell Medicine in New York, for example, runs pulmonary studies that include asthma evaluations with compensation for completed visits. The Brigham and Women's Hospital Asthma Research Center in Boston has offered compensation for longer-term studies spanning nearly two years. University-affiliated programs in Wisconsin, Florida, and Illinois post similar opportunities.
A practical approach is to check all three sources—ClinicalTrials.gov, a patient advocacy organization, and a local academic medical center—and cross-reference what you find. Some trials appear on multiple platforms, but others are only listed in one place.
What Actually Happens When You Join
The process begins with a screening visit, which is essentially a thorough asthma checkup. You will review your medical history with the research team, undergo lung function tests like spirometry, and likely provide a blood sample. This visit determines whether you meet the eligibility criteria—which might include factors like your current medication regimen, asthma control level, smoking history, and age.
Take Maria, a 34-year-old teacher in Phoenix who has lived with moderate asthma since childhood. She found a trial through the University of Arizona's research center and went through the screening process expecting to be turned away because her asthma was not "bad enough." Instead, the researchers confirmed she qualified for an observational study tracking how adults with moderate asthma respond to seasonal allergen changes. The screening itself gave her lung function data she had not received from her regular doctor in years—a detail that surprised her.
If you pass screening, the real commitment begins. Interventional trials might ask you to visit the clinic every two to four weeks for assessments, keep a daily symptom diary, and carry a peak flow meter. Some studies provide the investigational medication at no cost during the trial period, and others reimburse participants for travel and time. The range varies widely—shorter focus groups may offer modest stipends, while multi-year biologic trials can compensate participants more substantially for the dozens of visits required.
Throughout the process, you have the right to withdraw at any time. This is not a contract you cannot break. The informed consent document you sign at the beginning spells out every procedure, risk, and your right to walk away, and a good research coordinator will remind you of this repeatedly.
Questions Worth Asking Before You Commit
Walking into a screening visit with a prepared list of questions changes the dynamic. It signals that you are evaluating the trial as much as the trial is evaluating you.
Ask about the study's phase. Phase I trials test safety in small groups and carry the most uncertainty. Phase II studies explore dosing and effectiveness. Phase III trials, which involve larger populations and compare new treatments to existing standards, are the most common type you will encounter when searching for asthma studies. Phase IV research looks at treatments already approved, making it the lowest-risk option.
Ask what happens when the trial ends. Will you have the option to continue the treatment if it worked for you? Some trials include an open-label extension phase where all participants receive the active treatment. Others simply conclude, and you return to your previous care plan.
Ask about the placebo possibility. In many interventional asthma trials, participants are randomized into groups where some receive the investigational drug and others receive a placebo or standard treatment. You will not know which group you are in, and neither will the research team—this double-blind design is what makes the data reliable. But it also means you should be prepared for the possibility that you are not receiving the new therapy during the study period.
David, a 52-year-old contractor in Illinois, joined a biologic trial at Northwestern after his severe eosinophilic asthma stopped responding to his current regimen. "The thing that made me nervous was the placebo possibility," he said. "But the study coordinator explained that even the placebo group receives standard care—they do not just leave you untreated. That changed how I thought about it." His participation in the trial contributed to data that helped refine treatment protocols for patients with similar profiles.
Taking the Next Step
Asthma clinical trials are not for everyone, and they are certainly not a replacement for the relationship you have with your primary care physician or pulmonologist. But for people whose symptoms remain stubbornly uncontrolled, or for those who simply want to contribute to the science that shapes tomorrow's treatment options, they represent a concrete path forward.
Start by talking to your doctor. Many physicians are aware of local trials and can help you assess whether participation makes clinical sense for your situation. Then set aside an hour to browse ClinicalTrials.gov, the AAFA website, or the American Lung Association's trial finder. Bookmark the studies that interest you and reach out to the listed contact—usually a research coordinator who can answer preliminary questions over the phone.
The three a.m. reach for the rescue inhaler may not disappear overnight. But the studies enrolling today are building the evidence base for the treatments that will make that scene less common for the next generation of patients. You can be part of that effort, and you can do it on your own terms—informed, prepared, and clear-eyed about what clinical research actually involves.
研究の知恵